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Detection of clinically actionable mutations in diagnostic tumour specimens aids in the selection of targeted therapeutics. With an
ever increasing number of clinically signiicantmutations identiied, tumour genetic diagnostics is moving from single tomultigene
analysis. As it is still not feasible for routine diagnostic laboratories to perform sequencing of the entire cancer genome, our
approachwas to undertake targetedmutation detection. To optimise our diagnostic worklow, we evaluated three target enrichment
strategies using two next-generation sequencing (NGS) platforms (IlluminaMiSeq and Ion PGM).he target enrichment strategies
were Fluidigm Access Array custom amplicon panel including 13 genes (MiSeq sequencing), the Oxford Gene Technologies
(OGT) SureSeq Solid Tumour hybridisation panel including 60 genes (MiSeq sequencing), and an Ion AmpliSeq Cancer Hotspot
Panel including 50 genes (Ion PGM sequencing). DNA extracted from formalin-ixed parain-embedded (FFPE) blocks of eight
previously characterised cancer cell lines was tested using the three panels. Matching genomic DNA from fresh cultures of these
cell lines was also tested using the custom Fluidigm panel and the OGT SureSeq Solid Tumour panel. Each panel allowed mutation
detection of core cancer genes including KRAS, BRAF, and EGFR. Our results indicate that the panels enable accurate variant
detection despite sequencing from FFPE DNA.
1. Introduction
Genetic factors play a principal role in cancer predisposition,
initiation, and development [1–3]. hroughout cancer pro-
gression, the genome acquires somatic genetic and epigenetic
changes [4, 5]. Some mutations play a critical role in cancer
development by afecting key cancer “driver” genes. In con-
trast, some changes do not provide any selective advantage
and are termed “passenger” mutations [6]. A number of the
“driver” gene mutations are considered “actionable” as they
have diagnostic, prognostic, or predictive implications. In
addition, some of these mutations can be targeted by speciic
therapies and are commonly termed “druggable” variants [7].
Identiication of “actionable” mutations informs clinical
management and can be used to personalise cancer therapy.
his is proving to be safer and more efective than traditional
approaches [7, 8]. Many such genetic biomarkers are already
in clinical use. Examples include EGFR mutation status as
a predictive marker for sensitivity or resistance to anti-
EGFR therapies including erlotinib/geitinib in non-small
cell lung cancer (NSCLC) and BRAF mutation status as
a predictive marker for the B-Raf inhibitor, Vemurafenib,
associated with metastatic melanoma [7, 9–11]. Diferent
molecular techniques are in use in diagnostic laboratories to
assess oncogenic genetic biomarkers, including luorescence
in situ hybridisation (FISH), quantitative polymerase chain
reaction (Q-PCR) (for ampliications or rearrangements),
and Sanger sequencing and pyrosequencing (for point muta-
tions and small insertions or deletions).hese techniques are
frequently labour intensive, require large amounts of DNA,
and are relatively slow and expensive. hey oten have a high
failure rate and a limited scalability to expand analyses to
additional genes.
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As more clinically signiicant genetic biomarkers and tar-
geted therapies become available, diagnostic testing of these
genes has become more challenging. In addition to the larger
number of targets, challenges include poor quality formalin-
ixed parain-embedded (FFPE) DNA samples, small sample
size (e.g., needle biopsies), tumour sample heterogeneity, and
turn-around times [11, 12].he introduction of high through-
put and lower cost sequencing technologies, especially next-
generation sequencing (NGS), has revolutionised cancer
genomics research and diagnostics [7] which are rapidly
moving from single genemutation analysis to cancer genome
proiling [8, 13]. Nevertheless, sequencing of the entire cancer
genome by routine diagnostic laboratories is currently unfea-
sible as it remains expensive, time consuming, and labour
intensive.herefore, approaches to targeted resequencing are
necessary to capture and enrich speciic genomic regions of
interest (cancer gene panels) from DNA samples prior to
sequencing [14]. Several cancer gene panels and enrichment
methods have been developed recently and validated for
clinical diagnostic use by both research laboratories and
commercial companies [8, 11, 12, 15, 16]. In the Yorkshire
Regional Genetics Service (YRGS), IlluminaNGS technology
is routinely used to identify germline mutations causing
hereditary cancer [17, 18]. Recently, a manual PCR-based
enrichment method followed by NGS was developed and
is currently used to sequence actionable somatic mutations
in four key oncogenes: BRAF, EGFR, KRAS, and PIK3CA
[13]. However, the manual nature of the enrichment method
makes it technically challenging to expand the panel to
incorporate additional cancer genes.
In order to streamline and enhance the YRGS diagnos-
tic worklow, we evaluated three target enrichment strate-
gies using two NGS platforms (Illumina MiSeq and Ion
PGM). he target enrichment strategies were a Fluidigm
Access Array custom amplicon panel including 13 genes
(sequenced on the MiSeq), the Oxford Gene Technologies
(OGT) SureSeq Solid Tumour hybridisation panel including
60 genes (sequenced on the MiSeq), and an Ion AmpliSeq
Cancer Hotspot Panel including 50 genes (sequenced on
the IonPGM). Eight previously characterised cancer cell
lines were used to evaluate these approaches. DNA samples
extracted from FFPE blocks of these cell lines were tested
using the three panels. Matching genomic DNA samples
extracted from fresh cultures of these cell lines were also
tested using the customFluidigmpanel and theOGTSureSeq
Solid Tumour panel.
2. Materials and Methods
2.1. Samples. Eight previously characterised human bladder
cancer cell lines were used: 639V, 92-1, 97-7, J82, JO’N, KU-19-
19, LUCC3, and UM-UC3. Cell line identity was conirmed
using the Powerplex 16HS system (Promega, Southampton,
UK) [19]. he 8 cell lines contained 22 known mutations in
6 genes: BRAF, FGFR3, KRAS, NRAS, PIK3CA, and TP53
(Table 1). Supplementary Table 1, in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/478017,
provides further details on the mutation status of these cell
lines and the methods used in their previous molecular
characterisation.
2.2. Cell Culture and Fixation. Cells were cultured in suitable
culture medium supplemented with 10% foetal calf serum at
37∘C with 5% CO2. Harvested cells from conluent cultures
were washedwith phosphate bufered saline and resuspended
in CytoRich red ixative (Becton Dickinson, Oxford, UK)
before transport to the Leeds Cytopathology Department.
he cells were then pelleted and ixed following standard
operating procedures used to produce cell blocks from
clinical samples such as ine needle aspirates.
2.3. DNA Extraction. Genomic DNA (gDNA) from cul-
tured cells was extracted using a QIAamp DNA mini kit
(Qiagen, Manchester, UK) according to the manufacturer’s
instructions. DNA was extracted from FFPE sections using
a BioRobot EZ1 automated extractor (Qiagen, Manchester,
UK) according to the manufacturer’s instructions.
2.4. Target Enrichment. he design of Fluidigm enrichment
primers was undertaken by the Fluidigm design team with a
target size range of 150–160 bp. Target enrichment was per-
formed according to the manufacturer’s instructions using
the Access Array System for Illumina Sequencing Systems
v.G1 (Fluidigm UK Limited, London, UK). he SureSeq
hybridisation enrichment was performed according to the
manufacturer’s instructions (OGT) and with the support of
the OGT technical team.he Ion AmpliSeq enrichment (Life
Technologies Ltd., Paisley, UK) was performed according to
the manufacturer’s instructions. Supplementary Tables 2–4
list the targeted genes/exons in the three panels.
2.5. Sequencing. he Fluidigm custom panel and the SureSeq
panel libraries were sequenced on the Illumina MiSeq (Fresh
and FFPE gDNA were sequenced separately for each of the
panels), which was carried out in the Translational Genomics
Unit at St. James’s University Hospital. his used Illumina
MiSeq Reagent kit v2 (MS-102-2002) 300 cycles, Illumina
Experiment Manager v1.6.0 for building library plates and
creating the sample sheet, and the MiSeq Control Sotware
(MCS) v2.3.0.8 for monitoring the runs and quality control.
he Ion AmpliSeq panel libraries were sequenced on an Ion
PGM, which was carried out by Life Technologies team in
Paisley.
2.6. Bioinformatics Analysis. Sequence alignment and variant
calling for the Fluidigm custom panel was performed using
NextGene sotware v.2.3.4 (SotGenetics LLC, State College,
PA,USA) using deined parameters that included aminimum
read depth of 500x and nonreference allele frequency of
at least 5%. Sequence variants were visualised using the
NextGene Viewer v.2.3.4. For the SureSeq panel, analysis
was performed using the SureSeq Virtual Machine (SSVM)
v.0.3, and, for the Ion AmpliSeq panel, Ion Reporter sotware
v.4.0 was used. he data was iltered for variants in the 6
genes of interest and resulting variant calls were compared
between the three panels. Novel sequence variants identiied
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Table 1: Mutation status of the 8 bladder cancer cell lines.
Cell line
BRAF
(NM 004333.4)
FGFR3
(NM 00142.4)
KRAS
(NM 033360.2)
NRAS
(NM 002524.3)
PIK3CA
(NM 006218.2)
TP53
(NM 000546.5)
639V c.742C>T c.3197C>T c.743G>A
92-1
c.472C>T, c.670G>A,
c.682G>C, c.839G>C,
c.880G>A
97-7 c.746C>G c.120G>A,
c.221 236del16
J82 c.1948A>G c.811G>A, c.960G>C
JO’N c.38G>A c.853G>A
KU-19-19 c.182A>G
LUCC3 c.1786G>C c.1633G>A c.840 841insAA
UM-UC3 c.34G>T c.338T>G
in regions previously investigated were conirmed using
either bidirectional Sanger sequencing or pyrosequencing.
2.7. Sanger Sequencing. PCR products were enzymatically
puriied to remove residual primers and dNTPs using Illustra
ExoProStar (GE Lifesciences) following the manufacturer’s
instructions. All sequencing reactions were carried out using
the BigDye Terminator v.1.1 Cycle Sequencing Kit and were
performed on a 3730 Genetic Analyzer (Life Technologies
Ltd., Paisley, UK) according to the manufacturer’s instruc-
tions. he sequencing data was analysed with reference to
a control sequence trace using Mutation Surveyor sotware
v.3.20 (SotGenetics LLC, State College, PA, USA).
2.8. Pyrosequencing. Assays were performed by the Leeds
Cytogenetics Laboratory using the Pyromark Q96 ID instru-
ment (Qiagen, Manchester, UK) according to manufacturer’s
instructions. he pyrograms were analysed using Pyrogram
ID v.2.5 (Qiagen, Manchester, UK).
3. Results
3.1. Next-Generation Sequencing. MiSeq cluster densities of
811 K/mm2 and 880K/mm2 were achieved for the Fluidigm
custom panel libraries prepared using fresh gDNA and FFPE
gDNA, respectively. his corresponded to 15.21 and 16.62
million reads of which 90.63% and 35.37% passed ilter,
respectively. he fresh gDNA prepared pool yielded 2.1 Gb of
data while the FFPE gDNA prepared pool yielded 0.8Gb.he
percentage of bases that were ≥Q30 for each pool was 94.7%
(fresh gDNA) and 72.2% (FFPE gDNA).he per-sample read
distribution is displayed in Supplementary Table 5 which
indicates that the pooling was performed accurately.
MiSeq cluster densities of 788K/mm2 and 767K/mm2
were achieved for SureSeq Solid Tumour panel using fresh
gDNA and FFPE gDNA, respectively. his corresponded to
16.53 million and 16.21 million reads of which 72.58% and
73.31% passed ilter, respectively. Both SureSeq Solid Tumour
panel pools yielded 1.8 Gb of data and the percentage of
bases that were ≥Q30 per pool was approximately 88%. he
per-sample read distribution is displayed in Supplementary
Table 6, which indicates that the pooling was performed
accurately.
he Ion PGM sequencing output information is shown
in Supplementary Figure S1 as supplied by Life Technologies.
he per-sample read distribution is displayed in Supplemen-
tary Table 7, which indicates that the pooling was performed
accurately.
3.2. Analysis of Fresh Genomic DNA Samples. Using the
Fluidigm custom panel, 20 of the 22 known mutations were
correctly identiied. he two undetected mutations were
c.742C>T and c.746C>G in FGFR3 exon 7, whichweremissed
due to PCR failure. Two previously unknown mutations,
KRAS c.38G>A and TP53 c.783-2A>G, were identiied in cell
lines 92-1 and LUCC3, respectively. hese were conirmed
using Sanger sequencing (TP53 c.783-2A>G) and pyrose-
quencing (KRAS c.38G>A).
Using the SureSeq panel, all of the known mutations
were detected and the two novel mutations identiied by
the Fluidigm custom panel were conirmed. he depth of
coverage andmutant allele frequency of all of the variants are
summarised in Supplementary Table 8. Figure 1 summarises
the mutant allele frequency of the 24 mutations using the
Fluidigm panel and the SureSeq panel. For 21 of 22 mutations
detected successfully by both platforms, the mutant allele
frequency was comparable. he TP53 mutation c.960G>C
had a signiicantly diferent mutant allele frequency between
the 2 platforms: 42.1% (SureSeq panel) and 99.7% (Fluidigm
panel). Based on Sanger sequencing, the mutation appeared
to be heterozygous (∼50% mutant allele frequency). he
depth of coverage and mutant allele frequency of the variants
as detected by the Fluidigm and the SureSeq panels in fresh
gDNA are summarised in Supplementary Table 8. Notably,
three further variants (false positives) were identiied in the
SureSeq panel with <10% variant allele frequency (Table 2).
3.3. Analysis of FFPE Genomic DNA Samples. Using the
Fluidigm panel, 20 of the 24 mutations were successfully
detected. In addition to the FGFR3 exon 7 c.742C>T and
c.746C>G mutations, two other mutations in TP53 exon 4
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Table 2: Additional mutations identiied using the SureSeq Solid Tumour panel in fresh gDNA samples.
Cell line Gene Variant Variant allele frequency Read depth
97-7
TP53 (NM 000546.5)
c.853G>A 6.22% 225
639V c.1129A>C 6.48% 355
KU-19-19 c.1129A>C 7.61% 197
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Figure 1: Mutant allele frequency detected using fresh genomic
DNA. Comparison of mutant allele frequencies detected by the
Fluidigm panel and the SureSeq panel.
(c.120G>A) and intron 7 (c.783-2A>G) were not detected.
hese TP53 regions failed to amplify from most of the FFPE
DNA samples. Using the SureSeq panel, all of the mutations
were successfully detected.
Using the Ion AmpliSeq panel, 18 of the 24 muta-
tions were detected. he 6 missed mutations were in TP53
(c.120G>A, c.221 236del16, c.338T>G, c.670G>A, c.783-
2A>G, and c.960G>C), which are not among the hotspot
mutations detected by this panel. he depth of coverage and
mutant allele frequency of all of the variants are summarised
in Supplementary Table 9. Figure 2 summarises the mutant
allele frequency of the 24 mutations using the 3 panels.
he Fluidigm panel and the SureSeq panel had repro-
ducible mutant allele frequencies between fresh gDNA and
FFPE gDNA. here were four mutations with signiicant dif-
ferences in mutant allele frequency between the three panels
(Table 3). Based on Sanger sequencing, all were heterozygous
(50%).
Notably, three further variants (false positives) were
identiied in the SureSeq panel with <10% variant allele
frequency (Table 4). One of these, TP53 c.1129A>C, had also
been identiied at low variant allele frequency in fresh gDNA.
4. Discussion
Over the past few years, cancer treatment has entered a
new era in which diagnostic testing of clinically actionable
genetic markers allows selection of appropriate targeted
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Figure 2: Mutant allele frequencies detected in genomic DNA
extracted fromFFPE samples. Comparison ofmutant allele frequen-
cies detected by the Fluidigm panel, the SureSeq panel, and the Ion
AmpliSeq panel.
therapies, commonly referred to as personalised or stratiied
medicine [11]. We aimed to evaluate several NGS-based
tumour genotyping diagnostic panels to integrate and expand
the current diagnostic tumour genotyping assays performed
by the YRGS.
he target enrichment strategies were a custom Fluidigm
panel and 2 commercially available panels, the SureSeq Solid
Tumour hybridisation panel and the Ion AmpliSeq Cancer
Hotspot Panel.
he comparison between the three enrichment strategies
was performed on eight cancer cell lines in which 22
mutations had been previously identiied using either Sanger
sequencing, single strand conformation polymorphism
(SSCP) analysis, high-resolution melting (HRM) analysis, or
a SNaPshotMultiplex System (Life Technologies Ltd., Paisley,
UK). he NGS-based approaches identiied two mutations
that were previously not detected using conventional tech-
niques. hese results demonstrate the increased sensitivity
of using NGS in comparison to other existing techniques.
All three platforms were able to detect at least 75%
of the 24 mutations in the FFPE DNA samples: SureSeq
panel (100%), Fluidigm panel (83%), and Ion AmpliSeq panel
(75%). For the Fluidigm panel, one of the mutations not
detected was in FGFR3 exon 7.his amplicon had failed at the
design stage.he other threemutationswere detected in fresh
gDNA but not in FFPE.hese mutations were in regions that
underperformed in FFPE gDNA compared to fresh gDNA.
BioMed Research International 5
Table 3: Four mutations with signiicant diferences in mutant allele frequency between the three panels.
Cell line Gene Transcript Variant
Fluidigm
custom
panel
SureSeq Solid
Tumour panel
Ion AmpliSeq
Cancer Hotspot
Panel
Sanger sequencing
zygosity status
97-7 FGFR3 NM 00142.4 c.746C>G N/A 81.4% 34.6% Heterozygous
KU-19-19 NRAS NM 002524.3 c.182A>G 48.2% 50.5% 86.3% Heterozygous
J82 TP53 NM 000546.5 c.960G>C 85.7% 51.3% N/A Heterozygous
LUCC3 TP53 NM 000546.5 c.840 841insAA 57.7% 58.9% 96.4% Heterozygous
Table 4: Extra mutations identiied using the SureSeq Solid Tumour panel in FFPE gDNA.
Cell line Gene Variant Variant allele frequency Read depth
639V
TP53 (NM 000546.5)
c.113C>A 5.10% 294
KU-19-19 c.1129A>C 6.64% 271
LUCC3 c.1129A>C 5.10% 255
It is well established that FFPE tumour DNA samples are
challenging to amplify and sequence due to damage resulting
from the ixation process and due to sample heterogeneity.
his is likely to be one of the sensitivity diferences between
fresh and FFPE gDNA samples.However, some optimisations
may enhance the performance of the assay with FFPE
samples.hese include redesign of some of the target regions,
particularly those that frequently failed to amplify. Some
of these regions had lower read depth in comparison to
other targets using the fresh gDNA samples, indicating that
they were intrinsically more diicult to amplify. Moreover,
examination of theAgilent Bioanalyser traces for the 44 FFPE
gDNA libraries indicated that the tagging reaction was not
as eicient for the FFPE gDNA samples as demonstrated
by an abundance of unincorporated oligonucleotide adaptor
sequences. Optimisation of the tagging protocol is likely to
enhance the read depth of some of the target regions which
may help to increase sensitivity and speciicity.
For the Ion AmpliSeq panel, all of the “missed”mutations
were not included in the hotspot mutations covered by this
panel. herefore, the analytical sensitivity of the panel was
100%. Nevertheless, the clinical sensitivity may be reduced
due to the restricted nature of the hotspots panel and so
less common mutations may be missed. his is particularly
the case for tumour suppressor genes such as TP53, where
inactivating mutations may occur throughout the gene. For
such genes, coverage of all coding sequence is ideal.
he SureSeq panel sensitivity was 100%.However, average
read depth was signiicantly lower than the PCR-based
Fluidigm panel and the Ion AmpliSeq panel (Supplementary
Tables 5 and 6). Moreover, several false positives variants
were identiied within the TP53 gene. he OGT R&D and
bioinformatics teams followed up these variants. Following
detailed inspection, they concluded that these discrepancies
were independent of the hybridisation assay and that they
were an artefact of the bioinformatics pipeline. As the
genotyping is independent of the capture assay, in order to
resolve these issues, additional user reinement of base and
mapping quality score thresholds may be required.
5. Conclusions
he three platforms tested all showed acceptable perfor-
mance. However, custom panels with a smaller number
of clinically relevant and actionable targets and genes are
likely to be more suitable for diagnostic laboratories. Custom
designs and bioinformatics pipelines addressing both muta-
tion hotspots and the entire coding sequence of clinically
relevant genes will be required. Such custom panels will likely
reduce the cost of the assay and improve the depth of cov-
erage, which may help to reduce false positive variant calls.
Cost, DNA requirements, and turn-around times will also be
critical in choosing a platform for the diagnostic service.
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